Study Design

Study Design:

Patients Screened: Not giveen
Patients Enrolled: 90
Mean Follow Up: 39 months
Mean Patient Age: Controls: 53.9 years Diet only: 48.9 years Diet pl
Female: 0

Patient Populations:

Men referred for coronary angiography to investigate angina pectoris or other findings suggestive of CHD
Under 66 years of age
Plasma cholesterol concentrations above 6.0 mmol/L in two consecutive blood samples while on their usual diet

Exclusions:

Plasma cholesterol concentrations above 1.0 mmol/L
Patients already treated with lipid-lowering drugs
Fasting plasma triglyceride concentrations above 4 mmol/L
Remnant hyperlipidemia
Fasting glucose above 7 mmol/L
Cardiac failure
Myocardial infarction in the previous 8 weeks
Malignancy or other major organ disease
Accelerated hypertension
Initial angiographic or clinical findings indicating a need for coronary artery revascularization, or recent receipt of coronary artery revascularization

Primary Endpoints:

Change in mean absolute width of the coronary segment (MAWS).

Secondary Endpoints:

Death (by any cause)
Non-fatal myocardial infarction
Coronary artery bypass surgery or angioplasty during the trial
Stroke
Frequency and degree of angina
Change in antianginal medication

Drug/Procedures Used:

Diet-plus-cholestyramine group also received 8 g cholestyramine bid with meals.

Diet and diet-plus-cholestyramine groups received lipid-lowering diet, consisting of:
total fat intake: 27% of total energy
saturated fatty acid content: 8-1

Concomitant Medications:

β-blockers (35%)
Calcium agonists (34%)
Long-acting oral nitrates (24%)
Diuretics (19%)
Aspirin (18%)
Dipyridamole (13%)